Přihlásit se Zaregistrujte se zdarma

Výnosy R/R společnosti Starpharma

Jaká je hodnota metriky Výnosy R/R společnosti Starpharma?

Hodnota metriky Výnosy R/R společnosti Starpharma Holdings Limited je 131.75%

Jaká je definice metriky Výnosy R/R?

Roční růst tržeb za poslední 3 roky (Revenue Y/Y) představuje růst tržeb z roku na rok zprůměrovaný za poslední 3 roky.

The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.

Výnosy R/R společností v sektoru Health Care sektor na ASX ve srovnání se společností Starpharma

Čemu se věnuje společnost Starpharma?

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Firmy s metrikou výnosy r/r podobnou společnosti Starpharma